FARNUM RHONDA (SVP, Comm & Medical Affairs) sold 11.8% of their position (31.07K shares) of THERAVANCE BIOPHARMA, INC. on the open market
Open‑market sale worth $433.6K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 3/18/2026ACC: 0001898490-26-000004
Officer· SVP, Comm & Medical Affairs
Since Dec 2021
-31.07K
Net shares
Net seller
$433.6K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
31.07K disposed
Non-Derivative Transactions3
Ordinary Shares
Direct
Shares
−7.77K
Price / share
$13.92
Trade value
$108.09K
% of position
2.9%
3/16/2026
263.77K→256K
Ordinary Shares
Direct
Shares
−15.53K
Price / share
$14.00
Trade value
$217.48K
% of position
6.1%
3/16/2026
256K→240.47K
Ordinary Shares
Direct
Shares
−7.77K
Price / share
$13.92
Trade value
$108.07K
% of position
3.2%
3/16/2026
240.47K→232.70K
Total
Net shares
−31.07K
Net value
-$433.64K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Direct | 3/16/2026 | S · Sale | −7.77K | $13.92 | $108.09K | 2.9% | 263.77K | 256K |
| Ordinary Shares Direct | 3/16/2026 | S · Sale | −15.53K | $14.00 | $217.48K | 6.1% | 256K | 240.47K |
| Ordinary Shares Direct | 3/16/2026 | S · Sale | −7.77K | $13.92 | $108.07K | 3.2% | 240.47K | 232.70K |
| Total | −31.07K | -$433.64K | ||||||
Derivative Transactions0
No derivative transactions reported